Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Alessandra Borchiellini"'
Autor:
Augusto B. Federici MD, Rita Carlotta Santoro MD, Cristina Santoro MD, Lisa Pieri MD, Roberto Mario Santi MD, Giovanni Barillari MD, Alessandra Borchiellini MD, Alberto Tosetto MD, Ezio Zanon MD, Raimondo De Cristofaro MD, Esther Mairal MD, Roser Mir PhD
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 30 (2024)
Plasma-derived von Willebrand factor-containing factor VIII concentrates (pd-VWF/FVIII-C) are the mainstay of treatment in von Willebrand disease (VWD). Real-world data on efficacy and safety of these pd-VWF/FVIII-C are required. To retrospectively e
Externí odkaz:
https://doaj.org/article/4afed7a9b43643528a9fed511a516d6e
Autor:
Giuseppe Palumbo, Piero Farruggia, Ugo Ramenghi, Giovanna Russo, Alessandra Borchiellini, Marco Spinelli, Carlo Dufour, Fiorina Giona, Saverio Ladogana, Marco Zecca, Silverio Perrotta, Andrea Pession, Paola Giordano
Publikováno v:
Hematology, Vol 28, Iss 1 (2023)
ABSTRACTBackground Immune thrombocytopenia (ITP) is the most common acquired bleeding disorder. In both children and adults, the primary goal of any therapeutic approach consists of cessation of bleeding and its prevention. Several options are curren
Externí odkaz:
https://doaj.org/article/86ebea6f16584e74b5c230cc3fda77be
Autor:
Cristina Olgasi, Chiara Borsotti, Simone Merlin, Thorsten Bergmann, Patrick Bittorf, Adeolu Badi Adewoye, Nicholas Wragg, Kelcey Patterson, Andrea Calabria, Fabrizio Benedicenti, Alessia Cucci, Alessandra Borchiellini, Berardino Pollio, Eugenio Montini, Delfina M. Mazzuca, Martin Zierau, Alexandra Stolzing, Philip.M. Toleikis, Joris Braspenning, Antonia Follenzi
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 23, Iss , Pp 551-566 (2021)
Hemophilia A (HA) is a rare bleeding disorder caused by deficiency/dysfunction of the FVIII protein. As current therapies based on frequent FVIII infusions are not a definitive cure, long-term expression of FVIII in endothelial cells through lentivir
Externí odkaz:
https://doaj.org/article/7a58ac952d7247cb827b394f9103e931
Autor:
Cristina Dainese MD, Federica Valeri PhD, MD, Eleonora Pizzo MD, Alessandra Valpreda BS, Piera Sivera MD, Barbara Montaruli PhD, Annamaria Porreca PhD, Massimo Massaia PhD, MD, Benedetto Bruno PhD, MD, Alessandra Borchiellini MD
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 28 (2022)
The introduction Caplacizumab in the management of Immune thrombotic thrombocytopenic purpura (iTTP) has raised different questions, considering its cost-efficacy and the optimal immunosuppressive treatment (IST) to associate. A retrospective multice
Externí odkaz:
https://doaj.org/article/9553f5c910f6403189104352d782448d
Autor:
Federica Valeri, Jacopo Agnelli Giacchello, Cristina Dainese, Alessandra Valpreda, Barbara Montaruli, Enrico Dosio, Mario Boccadoro, Alessandra Borchiellini
Publikováno v:
Clinical Case Reports, Vol 8, Iss 3, Pp 531-534 (2020)
Abstract Practical, safe, and effective hemostatic approach to orthopedic surgery using Extended Half‐Life factor IX in hemophilia B. By intraindividual comparison, we found a lower FIX consumption, number of infusions, and cost compared to plasma
Externí odkaz:
https://doaj.org/article/684d04ee9105473b957e80cd9079173e
Autor:
Monica Carpenedo, Erminia Baldacci, Claudia Baratè, Alessandra Borchiellini, Francesco Buccisano, Giuseppina Calvaruso, Federico Chiurazzi, Bruno Fattizzo, Gaetano Giuffrida, Elena Rossi, Francesca Palandri, Potito Rosario Scalzulli, Sergio Mario Siragusa, Angelantonio Vitucci, Francesco Zaja
Publikováno v:
Therapeutic Advances in Hematology, Vol 12 (2021)
Introduction: In patients with primary immune thrombocytopenia (ITP), a short course of steroids is routinely given as first-line therapy. However, the response is often transient and additional therapy is usually needed. Thrombopoietin receptor agon
Externí odkaz:
https://doaj.org/article/f778d6c8959641f2847bc57d4ee14356
Autor:
Cristina Dainese, Federica Valeri, Marco Bardetta, Carola Sella, Annamaria Porreca, Alessandra Valpreda, Fabrizia Pittaluga, Giulio Mengozzi, Benedetto Bruno, Alessandra Borchiellini
Publikováno v:
Biomedicines, Vol 10, Iss 11, p 2674 (2022)
Both SARS-CoV-2 infection and vaccination have raised concern in immune-mediated diseases, including immune thrombocytopenic purpura (ITP) considering risk of de novo ITP development and ITP recurrence. Here, we report on data from a single-center re
Externí odkaz:
https://doaj.org/article/a5bd81acf746437f9fb1cd9bb777fd03
Autor:
Cristina Novembrino, Ilaria Quaglia, Angelo Claudio Molinari, Alessandra Borchiellini, Antonio Coppola, Rita Carlotta Santoro, Massimo Boscolo-Anzoletti, Eleonora Galbiati, Ezio Zanon, Alessandra Valpreda
Publikováno v:
Diagnostics, Vol 12, Iss 8, p 1999 (2022)
Recombinant porcine factor VIII (rpFVIII) is indicated for treating bleeding episodes in acquired haemophilia A, but there are few data regarding laboratory methods to adequately monitor treatment. This study involving three Italian laboratories aime
Externí odkaz:
https://doaj.org/article/401372c1250a4cd58e8557ebcf86b25a
Autor:
Elena Crisà, Marco Cerrano, Eloise Beggiato, Giulia Benevolo, Giuseppe Lanzarone, Paola Maria Manzini, Alessandra Borchiellini, Ludovica Riera, Mario Boccadoro, Dario Ferrero
Publikováno v:
Journal of Hematology & Oncology, Vol 10, Iss 1, Pp 1-4 (2017)
Abstract Pegylated interferon (peg-IFN) was proven by phase II trials to be effective in polycythemia vera (PV); however, it is not clear whether it could improve patient outcome compared to hydroxyurea (HU). Here, we present an observational study o
Externí odkaz:
https://doaj.org/article/5141d009ae64455891fb053726504d18
Autor:
Annarita Tagliaferri, Angelo Claudio Molinari, Flora Peyvandi, Antonio Coppola, Francesco Demartis, Chiara Biasoli, Alessandra Borchiellini, Dorina Cultrera, Raimondo De Cristofaro, Filomena Daniele, Paola Giordano, Emanuela Marchesini, Maurizio Margaglione, Renato Marino, Berardino Pollio, Paolo Radossi, Cristina Santoro, Rita Carlotta Santoro, Sergio Siragusa, Gianluca Sottilotta, Alberto Tosetto, Lydia Piscitelli, Maria Rosaria Villa, Ezio Zanon, Adele Finardi, Irene Schiavetti, Daniella Vaccari, Giancarlo Castaman
Publikováno v:
Haemophilia. 29:135-144
Introduction: Factor IX replacement therapy is used for treatment and prophylaxis of bleeding in haemophilia B. rIX-FP is an extended half-life albumin-fusion protein, which, in clinical studies, has demonstrated prolonged dosing intervals up to 21 d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87da219a054020001d456401727a99bf
https://doi.org/10.1111/hae.14689
https://doi.org/10.1111/hae.14689